Seeking Alpha

Halozyme Therapeutics (HALO) +18.6% premarket after the European Medicines Agency approves...

Halozyme Therapeutics (HALO) +18.6% premarket after the European Medicines Agency approves partner Baxter (BAX) for the use of HALO's HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Upon receiving marketing authorization from the EC, BAX plans to launch HyQvia in some European countries later this year.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)